
Whitney Goldsberry, MD, discusses the potential risk of secondary malignancies in patients with ovarian cancer receiving PARP inhibitors.

Your AI-Trained Oncology Knowledge Connection!


Whitney Goldsberry, MD, discusses the potential risk of secondary malignancies in patients with ovarian cancer receiving PARP inhibitors.

Whitney Goldsberry, MD, discusses considerations for selecting a PARP inhibitor in the maintenance treatment of ovarian cancer.